NIH Defends Choice Of Exclusive Zika Vaccine License Recipient Amid Conflict-Of-Interest Allegations
CQ HealthBeat: NIH Pushes Back on Zika Vaccine Conflict Allegation
“The government’s premier medical research agency is refuting allegations that its choice to help bring a Zika vaccine to market was a conflict of interest. … In October, [NIH] announced that it was planning to grant an exclusive license to California-based PaxVax, Inc., a small pharmaceutical company that specializes in vaccines, to further develop the product and eventually bring it to market. But Ken Kelley, the founder and former chief executive of PaxVax, is currently an adviser in the vaccine research center at the National Institute for Allergy and Infectious Diseases, the NIH division that has been researching the Zika vaccine…” (Siddons, 11/15).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.